Faruqi & Faruqi, LLP Announces Investigation of Catalyst Health Solutions, Inc.

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Catalyst Health Solutions, Inc. (“Catalyst” or the “Company”) (NASDAQ: CHSI) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to SXC Health Solutions Corp. (“SXC”) (NASDAQ: SXCI, TSX: SXC) in a cash-and-stock transaction valued at approximately $4.4 billion. Under the terms of the merger agreement, Catalyst shareholders will receive $28.00 in cash and 0.6606 shares of SXC stock for each Catalyst share, which implies a purchase price of $81.02 per each share of Catalyst common stock based on the closing stock prices of SXC and Catalyst on April 17, 2012.